News|Articles|February 20, 2024

Understand Links Between RSV, Pediatric Asthma, and COVID-19

RSV can exacerbate asthma development by causing damage to the tissue in the airways, promoting inflammation and increasing airway hyper-responsiveness

Respiratory syncytial virus (RSV) can cause lower respiratory tract infections such as acute bronchiolitis and spreads through respiratory droplets and close contact. Annually, RSV results in approximately 33 million acute cases of lower respiratory tract infections, 3.2 million hospitalizations, and more than 100,000 deaths in pediatric patients younger than 5 years.

Studies have linked severe RSV bronchiolitis in childhood to the development of wheezing, asthma, and airway remodeling, but the connection was never well understood. The European Journal of Clinical Microbiology & Infectious Diseases published a review article looking at RSV and its implications in the development of pediatric asthma. The review also highlights how the virus causes similar disruptions in the immune system to SARS-CoV-2, the virus that causes COVID-19.

This study provided evidence that RSV can exacerbate asthma development by causing damage to the tissue in the airways, promoting inflammation and increasing airway hyper-responsiveness. These effects eventually cause airway remodeling.

Although this review provides extensive discussion on RSV’s possible involvement in the development of pediatric asthma, the data are insufficient to confirm it as an independent cause.

During the COVID-19 pandemic, the prevalence of RSV decreased because of restrictive public measures such as social distancing and masking. RSV and SARS-COV-2 both have single-strand RNA and cause similar disruptions in immune response, leading to increased reinfection and risk of severe tissue injury.

Both viruses cause dysregulation of TLR signaling, which helps with the initial recognition of invading pathogens, and both increase the activity of NLRP3 inflammasomes, which leads to increased inflammation in the body. The viruses also suppress HLA-DR activity, which increases disease severity in infants for RSV and adults for COVID-19.

RSV infection is a severe health concern, and prevention is imperative because it may decrease the incidence of pediatric asthma. This review provides insight into future preventative and treatment methods for RSV by using lessons learned from the pandemic’s public health measures and insights on specific immunologic changes from RSV and COVID-19 virus.

About the Author

Ellie Provisor, PharmD, is a pharmacy program coordinator at Maine General Medical Center in Augusta, Maine.

Reference
Su P, Jiang C, Zhang Y. The implication of infection with respiratory syncytial virus in pediatric recurrent wheezing and asthma: knowledge expanded post-COVID-19 era. Eur J Clin Microbiol Infect Dis. Published online December 28, 2023. doi:10.1007/s10096-023-04744-0

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME